MARX Biotech Co., Ltd. (7731) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of MARX Biotech Co., Ltd. TWD 1.40, price TWD 4.21, upside -66.8%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MARX Biotech Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
MARX Biotech Co., Ltd. engages in the online retail of men's health food and cosmeceutical products. The company was founded in 2015 and is based in New Taipei City, Taiwan.
Stock analysis
MARX Biotech Co., Ltd. (7731) currently trades at 4.21 TWD, while our model-based Fair Value estimate is 1.40 TWD, implying the stock looks roughly 200.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 3.82 TWD per share, and 0 of the 10 models we run sit above the 4.21 TWD price.
Bear case: the Asset-Based group reads lowest at 0.4600 TWD, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.6100 TWD (bear) to 1.75 TWD (bull), the price of 4.21 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
MARX Biotech Co., Ltd. reported revenue of 636M TWD in FY2025 versus 97.6M TWD in FY2021, a compound +59.8%/yr. Reported net income was 42.9M TWD in FY2025, compounding +32.9%/yr from FY2021.
Key figures
Market cap 2.6B TWD (≈ $82.3M) · P/E ratio 52.6 · P/S ratio 3.55 · EPS (TTM) 0.0800 TWD · Net margin 6.8% · Return on equity 13.8% · Return on assets (EBIT) −2.7% · Operating margin −32.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −67%, 7731 screens richer than that median.
Fair Value models
Bear 0.6100 TWDFair Value 1.40 TWDBull 1.75 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0587 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+79.1%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.8%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → −22%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−67% · Bottom 25%
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets−11% · Bottom 25%
Net margin (TTM)7% · Top 25%
Operating margin (TTM)−33% · Bottom 25%
Growth and dividend
Revenue growth−19% · Bottom 25%
Balance sheet
Debt / equity0.46× · Highest 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)52.6× · Priciest 25%
P/B7.29× · Priciest 25%
P/S (TTM)4.12× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 19
PAST (return on equity)55· sector 22
HEALTH (low debt)77· sector 96
DIVIDEND (yield)0· sector 64
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is MARX Biotech Co., Ltd. (7731) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1.40 TWD versus a price of 4.21 TWD, about −67% upside (overvalued).
What is the fair value of 7731?
Our model-based fair value for MARX Biotech Co., Ltd. is 1.40 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 4.21 TWD.
What is the quality score of 7731?
MARX Biotech Co., Ltd. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MARX Biotech Co., Ltd. (7731)?
Our model-based price target is the fair value of 1.40 TWD (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 0.6100 TWD, optimistic scenario 1.75 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the MARX Biotech Co., Ltd. stock forecast for 2026?
Our models put fair value at 1.40 TWD, about −67% upside versus a price of 4.21 TWD (overvalued). Cautious scenario 0.6100 TWD, optimistic scenario 1.75 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of MARX Biotech Co., Ltd. (7731)?
MARX Biotech Co., Ltd. reported trailing-twelve-month revenue of about 636M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of MARX Biotech Co., Ltd. (7731)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MARX Biotech Co., Ltd. it is 1.40 TWD per share (as of Sep 24, 2026), against a price of 4.21 TWD. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is MARX Biotech Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7731 trades above its calculated fair value: price 4.21 TWD, fair value 1.40 TWD, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7731?
No. The price is what the market pays today (4.21 TWD); the fair value is what the company's own numbers justify (1.40 TWD). For MARX Biotech Co., Ltd. the two are 2.81 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is MARX Biotech Co., Ltd. worth?
The market values MARX Biotech Co., Ltd. at about 2.6B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 4.21 TWD; our models calculate a fair value of 1.40 TWD per share.
What do the bullish and bearish scenarios say about 7731?
Our models span a range for MARX Biotech Co., Ltd.: cautious scenario 0.6100 TWD, base 1.40 TWD, optimistic 1.75 TWD per share (as of Sep 24, 2026, price 4.21 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7731?
MARX Biotech Co., Ltd. trades at a price-to-earnings ratio of 52.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.40 TWD is built from several models across several years. Other multiples: P/B 7.3, P/S 4.1.
How solid is the balance sheet of MARX Biotech Co., Ltd. (7731)?
Balance-sheet figures for MARX Biotech Co., Ltd. (as of Sep 24, 2026): return on equity 13.8%, debt of 0.46 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 7731 from its 52-week high?
MARX Biotech Co., Ltd. trades at 4.21 TWD, about 53% below its 52-week high of 9.01 TWD and 7% above the low of 3.94 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 1.40 TWD is for.
Which stocks are comparable to MARX Biotech Co., Ltd.?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MARX Biotech Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 4.21 TWD, calculated fair value 1.40 TWD (−67%), Quality Score 31/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7731 calculated?
We run MARX Biotech Co., Ltd. through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.40 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. MARX Biotech Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MARX Biotech Co., Ltd. (7731)?
The closing price on Sep 24, 2026 was 4.21 TWD. Our model-based fair value is 1.40 TWD, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MARX Biotech Co., Ltd. right now?
The price sits above even our optimistic bull case (1.75 TWD). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (0.6100 TWD to 1.75 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of MARX Biotech Co., Ltd.
How large is the market capitalisation of MARX Biotech Co., Ltd. (7731)?
The market capitalisation of MARX Biotech Co., Ltd. is 2.6B TWD (≈ $82.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MARX Biotech Co., Ltd. (7731)?
The price-to-sales ratio of MARX Biotech Co., Ltd. is 3.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MARX Biotech Co., Ltd. (7731)?
Earnings per share at MARX Biotech Co., Ltd. are 0.0800 TWD (price ÷ EPS = P/E 52.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MARX Biotech Co., Ltd. (7731)?
The net margin of MARX Biotech Co., Ltd. is 6.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MARX Biotech Co., Ltd. (7731)?
The return on equity (ROE) of MARX Biotech Co., Ltd. is 13.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MARX Biotech Co., Ltd. (7731)?
On an EBIT basis the return on assets of MARX Biotech Co., Ltd. is −2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MARX Biotech Co., Ltd. (7731)?
The operating margin of MARX Biotech Co., Ltd. is −32.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MARX Biotech Co., Ltd. (7731)?
Revenue at MARX Biotech Co., Ltd. is growing −19.1% versus a year earlier (3y avg +79.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MARX Biotech Co., Ltd. (7731) generate?
The free cash flow of MARX Biotech Co., Ltd. is −163M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MARX Biotech Co., Ltd. (7731) carry?
The net debt of MARX Biotech Co., Ltd. is 275M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch MARX Biotech Co., Ltd. in the live analysis
One click puts MARX Biotech Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
